Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Ryzodeg Offers Glycemic Control With Fewer Injections

September 18, 2014 9:17 am | News | Comments

Data presented by Novo Nordisk show that Ryzodeg (insulin degludec/insulin aspart), administered twice daily, provides successful glycemic control with fewer injections than a basal-bolus regimen. Read more...            

TOPICS:

BI, CureVac Collaborate on Next-Gen Lung Cancer Immunotherapy

September 18, 2014 9:09 am | News | Comments

Boehringer Ingelheim and CureVac jointly announced an exclusive global license and development collaboration focusing on CureVac’s CV9202, a novel investigational therapeutic mRNA vaccine in early clinical development for the treatment of lung cancer. Read more...

TOPICS:

UK Nurse Will Give Blood to Treat U.S. Ebola Patient

September 18, 2014 9:01 am | by Maria Cheng, AP Medical Writer | News | Comments

A British nurse who survived Ebola has traveled to the United States to donate blood to an American still battling the disease, an experimental measure some scientists think can help patients fight off the virus. Read more...       

TOPICS:
Advertisement

Bayer to Split Off Polymer Division

September 18, 2014 7:40 am | News | Comments

German pharmaceuticals and chemicals company Bayer AG says it plans a separate stock listing for its polymer division. The move is part of an effort to focus the group on its health care and crop science businesses. Read more...     

TOPICS:

Experts Want Limits on Testosterone Drug Use

September 17, 2014 6:39 pm | by Matthew Perrone, AP Health Writer | News | Comments

U.S. health experts said Wednesday there is little evidence that testosterone-boosting drugs are effective for treating common signs of aging in men and that their use should be narrowed to exclude millions of Americans currently taking them. Read more...

TOPICS:

Gilead Releases Phase 2 Pancreatic Cancer Data

September 17, 2014 3:28 pm | News | Comments

Gilead Sciences Inc. announced results from a Phase 2 study evaluating simtuzumab, an investigational inhibitor of lysyl oxidase-like-2 (LOXL2), in combination with gemcitabine for patients with previously untreated advanced pancreatic cancer. Read more...

TOPICS:

Covance, Frenova Renal Research Collaborate on Kidney, Renal Diseases

September 17, 2014 3:24 pm | News | Comments

Covance Inc. and Frenova Renal Research announced a new research collaboration designed to find more effective treatments for patients living with chronic kidney disease (CKD) and end stage renal disease (ESRD). Read more...        

TOPICS:

Lilly Sells Failed Oncology Drug to Denovo Biopharma

September 17, 2014 3:18 pm | News | Comments

Denovo Biopharma LLC announced that it has acquired enzastaurin, a late-stage oncology drug, from Eli Lilly and Co. Denovo gains all rights to develop, manufacture and commercialize enzastaurin globally. Read more...           

TOPICS:
Advertisement

Cancer Progress Report: Research is Transforming Lives

September 17, 2014 3:10 pm | News | Comments

Research continues to fuel significant advances against cancer. This progress has been spurred by federal investments in the NIH and National Cancer Institute, according to the American Association for Cancer Research's fourth annual Cancer Progress Report. Read more...

TOPICS:

Sun Pharma Licenses Merck Psoriasis Drug for $80M

September 17, 2014 3:02 pm | News | Comments

Merck is licensing an experimental psoriasis drug to Indian drugmaker Sun Pharmaceuticals, the companies said Wednesday. Sun will pay Merck $80 million upfront and will gain the right to market the drug, called tildrakizumab. Read more...    

TOPICS:

1st Volunteer Gets Experimental Ebola Vaccine

September 17, 2014 12:46 pm | News | Comments

British scientists say a former nurse has become the first person in the country to receive an experimental Ebola vaccine in an early trial to test its safety. Read more...                       

TOPICS:

Sanofi Enters Groundbreaking Heart Disease Collaboration with MyoKardia

September 17, 2014 10:57 am | News | Comments

Sanofi and MyoKardia Inc. announced a worldwide collaboration to discover and develop first-of-its-kind targeted therapeutics for heritable heart diseases known as cardiomyopathies, the most common forms of heart muscle disease. Read more...   

TOPICS:

EMD Serono, Sutro Biopharma Partner on ADCs

September 17, 2014 10:52 am | News | Comments

EMD Serono Inc., a subsidiary of Merck KGaA, and Sutro Biopharma, a biopharmaceutical company developing antibody drug conjugates and bispecific antibodies, announced a collaboration and license agreement to develop antibody drug conjugates (ADCs). Read more...

TOPICS:

Merck Diabetes Drug Hits Endpoints in Japanese Study

September 17, 2014 10:44 am | News | Comments

Merck announced the presentation of the first data from the Phase 3 clinical development program for omarigliptin, Merck’s investigational once-weekly DPP-4 inhibitor for the treatment of type 2 diabetes. Read more...         

TOPICS:

Glenmark's TRPA1 Antagonist Excels in Phase 2a

September 17, 2014 10:33 am | News | Comments

Glenmark Pharmaceuticals announced that its first-in-class Transient Receptor Potential Ankyrin 1 antagonist, GRC 17536, has shown positive data in a Phase 2a study conducted on 138 patients in Europe and India. Read more...       

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading